id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
DEA-2023-0149-0005,DEA,DEA-2023-0149,Schedules of Controlled Substances: Placement of Zuranolone in Schedule IV,Rule,,2024-08-14T04:00:00Z,2024,8,2024-08-14T04:00:00Z,,2024-09-03T22:47:05Z,2024-18087,0,0,0900006486643896
DEA-2023-0149-0002,DEA,DEA-2023-0149,DEA1258 Zuranolone Eight Factors of Analysis September 2023,Supporting & Related Material,,2023-10-31T04:00:00Z,2023,10,,,2023-10-31T17:39:29Z,,0,0,09000064861a5b33
DEA-2023-0149-0001,DEA,DEA-2023-0149,Schedules of Controlled Substances: Placement of Zuranolone in Schedule IV,Rule,,2023-10-31T04:00:00Z,2023,10,2023-10-31T04:00:00Z,2023-12-01T04:59:59Z,2023-11-16T02:00:24Z,2023-23982,0,0,090000648619fc3f
DEA-2023-0149-0003,DEA,DEA-2023-0149,ASH to DEA Letter and 8FA Zuranolone 12Jul2023,Supporting & Related Material,,2023-10-31T04:00:00Z,2023,10,,,2023-10-31T17:39:40Z,,0,0,09000064861a5b32